Metraipolis › archive › dc_db9447e7d05b

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42358981
DOI
10.3389/fimmu.2026.1840323
License (as archived)
solo-consultazione
Archived
2026-10-31T15:05:06.690Z
SHA-256 of the archived text
791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612
Stable URL of this page
https://metraipolis.com/documento/dc_db9447e7d05b

How to cite

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981 — Europe PMC (en), https://europepmc.org/article/MED/42358981 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_db9447e7d05b (Metraipolis archive dc_db9447e7d05b, sha256 791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612)
BibTeX
@misc{dcdb9447e7d05b,
  title = {Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event… — Europe PMC PMID:42358981},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42358981},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_db9447e7d05b; sha256 791e9ab7451865240a5f2e529087a83979a3768228b0e00a05f306e401741612},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358981. Agents can read the archived copy with the MCP tool read_document.